Milestone Pharmaceuticals (MIST)
(Delayed Data from NSDQ)
$1.48 USD
-0.03 (-1.99%)
Updated Jul 29, 2024 04:00 PM ET
After-Market: $1.47 -0.01 (-0.68%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Price, Consensus and EPS Surprise
MIST 1.48 -0.03(-1.99%)
Will MIST be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for MIST based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MIST
Milestone Pharmaceuticals (MIST) Upgraded to Buy: Here's What You Should Know
Down -43.64% in 4 Weeks, Here's Why Milestone Pharmaceuticals (MIST) Looks Ripe for a Turnaround
MIST: What are Zacks experts saying now?
Zacks Private Portfolio Services
Milestone Pharma (MIST) Down on Regulatory Update for Etripamil
Milestone Pharmaceuticals (MIST) Upgraded to Buy: Here's Why
Here's Why Milestone Pharmaceuticals (MIST) is Poised for a Turnaround After Losing 14.5% in 4 Weeks
Other News for MIST
Milestone Pharmaceuticals (MIST) Receives a Buy from TD Cowen
Piper Sandler Reaffirms Their Buy Rating on Milestone Pharmaceuticals (MIST)
Milestone Pharmaceuticals to Host KOL Event for Investors ?Learnings from the Field: Expert Perspectives on PSVT in the Community Setting? on June 20, 2024
Milestone? Pharmaceuticals to Participate in the Upcoming Jefferies Global Healthcare Conference
Strong Buy Rating for Milestone Pharmaceuticals Amidst Promising CARDAMYST Prospects and Market Strategy